Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial
Streptococcus pneumoniae infection is a major global public health concern in older adults, especially as life expectancy continues to increase in most countries, including India. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) with the ability to enhance immunity (immunologic memory) o...
| Автори: | , , , , , , , , , |
|---|---|
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Taylor & Francis Group
2017-09-01
|
| Серія: | Human Vaccines & Immunotherapeutics |
| Предмети: | |
| Онлайн доступ: | http://dx.doi.org/10.1080/21645515.2017.1331796 |